EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer

Rinkee Kumari, Elaheh Sadat Hosseini, Kristen E Warrington, Tyler Milonas, Kyle K Payne iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24108722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rinkee Kumari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Immunology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, V Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of current immunotherapies remains limited in many solid epithelial malignancies. Recent investigations into the biology of butyrophilin (BTN) and butyrophilin-like (BTNL) molecules, however, suggest these molecules are potent immunosuppressors of antigen-specific protective T cell activity in tumor beds. BTN and BTNL molecules also associate with each other dynamically on cellular surfaces in specific contexts, which modulates their biology. At least in the case of BTN3A1, this dynamism drives the immunosuppression of αβ T cells or the activation of Vγ9Vδ2 T cells. Clearly, there is much to learn regarding the biology of BTN and BTNL molecules in the context of cancer, where they may represent intriguing immunotherapeutic targets that could potentially synergize with the current class of immune modulators in cancer. Here, we discuss our current understanding of BTN and BTNL biology, with a particular focus on BTN3A1, and potential therapeutic implications for cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesNeoplasmsHumansButyrophilinsImmunity, CellularAntigensReceptors, Antigen, T-Cell, gamma-deltaLymphocyte ActivationAntigens, CD

Stichwörter der Autor:innen

butyrophilinsimmune oncologyimmune suppressionimmunotherapyγδ T cells

Substanzen

ButyrophilinsAntigensReceptors, Antigen, T-Cell, gamma-deltaBTN3A1 protein, humanAntigens, CD

Autor:innen und Institutionen

  • Medical Immunology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08901, USA.
  • Cellular and Molecular Pharmacology, Rutgers School of Graduate Studies, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, USA.
  • Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA.

ORCID-Profile: Kyle K Payne

Förderung

  • NCI NIH HHS
  • NIH HHS
  • V Foundation for Cancer Research
  • New Jersey Health Foundation
  • New Jersey Commission on Cancer Research
  • Ovarian Cancer Research Alliance
  • National Institutes of Health

Zitieren

APA

Kumari, R., Hosseini, E. S., Warrington, K. E., Milonas, T., & Payne, K. K. (2023). Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108722

Vancouver

Kumari R, Hosseini ES, Warrington KE, Milonas T, Payne KK. Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108722

BibTeX
@article{Kumari2023,
  author = {Kumari, Rinkee and Hosseini, Elaheh Sadat and Warrington, Kristen E and Milonas, Tyler and Payne, Kyle K},
  title = {Butyrophilins: Dynamic Regulators of Protective T Cell Immunity in Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24108722}
}
Kostenlos starten →